Tafolecimab is under investigation in clinical trial NCT04031742 (A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia).
在控制饮食的基础上,与他汀类药物、或者与他汀类药物及其他降脂疗法联合用药,用于在接受中等剂量或中等剂量以上他汀类药物治疗,仍无法达到低密度脂蛋白胆固醇(LDL-C)目标的原发性高胆固醇血症(包括杂合子型家族性和非家族性高胆固醇血症)和混合型血脂异常的成人患者。
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.